Who to call at CG Oncology, Inc., and when
Fundz watches for the moments CG Oncology, Inc. starts buying, and tells you who to reach.
- An alert the day CG Oncology, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at CG Oncology, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at CG Oncology, Inc.. With Fundz connected, it knows.
CG Oncology, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
cgoncology.comThe seat is still open. No replacement has been named 345 days after this filing.
See every company with multiple executive changes →AI Executive Summary
AI-powered analysis of 8-K filing content
CG Oncology's interim principal financial and accounting officer, Robert Lapetina, resigned effective November 30, 2025. The company appointed Jim DeTore, a former biotech CFO engaged through Monomoy Advisors, LLC, to the role starting November 17, 2025, so finance leadership is now held by a consultant on a short-term arrangement.
Key Takeaways
Robert Lapetina resigned as interim principal financial and accounting officer, with the resignation effective November 30, 2025.
Jim DeTore was appointed principal financial and accounting officer effective November 17, 2025, and will serve through Monomoy Advisors, LLC under a Consulting Agreement rather than as a direct emplo
3 more takeaways
Related Filings (6)
6 more filings from CG Oncology, Inc. in the last 90 days
Filing Overview
What This Means
CG Oncology, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.